CIK 0001869105 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
BridgeBio Oncology Therapeutics, Inc.
Sign in to watch- Ticker
- BBOT
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 857 702 0377
- Business address
- 256 E. GRAND AVENUE, SUITE 104, SOUTH SAN FRANCISCO, CA, 94080
- Former names
- Helix Acquisition Corp. II
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-08-26 | MCCORMICK FRANK Director | Grant or award · Stock Option (Right to Buy) | +91,076 | 91,076 | ||
| 2025-08-26 | Bauer Jake Director | Grant or award · Stock Option (Right to Buy) | +138,193 | 138,193 | ||
| 2025-08-26 | Beltran Pedro Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +357,177 | 357,177 | ||
| 2025-08-26 | Ben Yong Chief Med & Dev Officer | Grant or award · Stock Option (Right to Buy) | +357,177 | 357,177 | ||
| 2025-08-26 | Wallace Eli M. Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +499,731 | 499,731 | ||
| 2025-08-26 | Mehra Uneek Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +633,570 | 633,570 | ||
| 2025-08-11 | Chen Bihua Director | Option exercise | +4,172,126 | 4,681,126 | ||
| 2025-08-11 | Chen Bihua Director | Returned to the company | −152,940 | 4,528,186 | ||
| 2025-08-11 | Chen Bihua Director | Grant or award | +760,496 | $10.72 | $8.2M | 2,187,536 |
| 2025-08-11 | Chen Bihua Director | Grant or award | +639,110 | $10.72 | $6.8M | 1,542,710 |
| 2025-08-11 | Chen Bihua Director | Grant or award | +5,598,425 | $10.72 | $60.0M | 5,667,785 |
| 2025-08-11 | Chen Bihua Director | Grant or award | +1,905,046 | 1,905,046 | ||
| 2025-08-11 | Chen Bihua Director | Grant or award | +1,762,760 | 3,305,470 | ||
| 2025-08-11 | Chen Bihua Director | Grant or award | +284,571 | 5,952,356 | ||
| 2025-08-11 | Chen Bihua Director | Returned to the company · Class B ordinary shares | −307,874 | 4,172,126 | ||
| 2025-08-11 | Chen Bihua Director | Option exercise · Class B ordinary shares | −4,172,126 | 0 | ||
| 2025-08-11 | Holman Albert A III Former Director | Option exercise | +30,000 | 30,000 | ||
| 2025-08-11 | Holman Albert A III Former Director | Option exercise · Class B ordinary shares | −30,000 | 0 | ||
| 2025-08-11 | McKenna Mark C. Former Director | Option exercise | +30,000 | 30,000 | ||
| 2025-08-11 | McKenna Mark C. Former Director | Option exercise · Class B ordinary shares | −30,000 | 0 |
Page 3 of 4 · 69 trades